J Czernin

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Clinical applications of FDG-PET in oncology
    J Czernin
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic, UCLA School of Medicine, Los Angeles, California, USA
    Acta Med Austriaca 29:162-70. 2002
  2. pmc FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas
    Matthias R Benz
    Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095 1782, USA
    Sarcoma 2010:143540. 2010
  3. ncbi request reprint Clinical PET/CT imaging: promises and misconceptions
    J Czernin
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center Nuclear Medicine, David Geffen School of Medicine at UCLA, Los Angeles 90095 6948, USA
    Nuklearmedizin 44:S18-23. 2005
  4. doi request reprint PET/CT imaging: The incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination
    Johannes Czernin
    Department of Molecular and Medical Pharmacology, Ahmanson Biological, Imaging Center Nuclear Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 6948, USA
    Eur J Radiol 73:470-80. 2010
  5. ncbi request reprint Molecular imaging in the development of cancer therapeutics
    Johannes Czernin
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Annu Rev Med 57:99-118. 2006
  6. ncbi request reprint Cigarette smoking and coronary blood flow
    Johannes Czernin
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Division, University of California Los Angeles School of Medicine, Los Angeles, CA, USA
    Prog Cardiovasc Dis 45:395-404. 2003
  7. ncbi request reprint Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006
    Johannes Czernin
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic Nuclear Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California 90095 6948, USA
    J Nucl Med 48:78S-88S. 2007
  8. pmc Molecular mechanisms of bone 18F-NaF deposition
    Johannes Czernin
    Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095 1782, USA
    J Nucl Med 51:1826-9. 2010
  9. doi request reprint Breast cancer
    Johannes Czernin
    Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA
    Methods Mol Biol 727:141-70. 2011
  10. ncbi request reprint Positron emission tomography scanning: current and future applications
    Johannes Czernin
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic, UCLA School of Medicine, 10833 LeConte Avenue, Los Angeles, California 90095 6942, USA
    Annu Rev Med 53:89-112. 2002

Detail Information

Publications81

  1. ncbi request reprint Clinical applications of FDG-PET in oncology
    J Czernin
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic, UCLA School of Medicine, Los Angeles, California, USA
    Acta Med Austriaca 29:162-70. 2002
    ....
  2. pmc FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas
    Matthias R Benz
    Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095 1782, USA
    Sarcoma 2010:143540. 2010
    ..Conclusion. These results suggest that changes in FDG-SUVmax at the end of neoadjuvant treatment can identify histopathologic responders and non-responders in adult primary bone sarcoma patients...
  3. ncbi request reprint Clinical PET/CT imaging: promises and misconceptions
    J Czernin
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center Nuclear Medicine, David Geffen School of Medicine at UCLA, Los Angeles 90095 6948, USA
    Nuklearmedizin 44:S18-23. 2005
    ....
  4. doi request reprint PET/CT imaging: The incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination
    Johannes Czernin
    Department of Molecular and Medical Pharmacology, Ahmanson Biological, Imaging Center Nuclear Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 6948, USA
    Eur J Radiol 73:470-80. 2010
    ..Finally, the recently emerging evidence of a substantial impact of PET/CT imaging on patient management is presented...
  5. ncbi request reprint Molecular imaging in the development of cancer therapeutics
    Johannes Czernin
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Annu Rev Med 57:99-118. 2006
    ..We conclude with a proposal to integrate molecular imaging into the drug development process...
  6. ncbi request reprint Cigarette smoking and coronary blood flow
    Johannes Czernin
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Division, University of California Los Angeles School of Medicine, Los Angeles, CA, USA
    Prog Cardiovasc Dis 45:395-404. 2003
    ..Finally, the coronary endothelial and peripheral arterial vasomotor dysfunction observed in active and passive healthy smokers appear to be to some degree reversible...
  7. ncbi request reprint Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006
    Johannes Czernin
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic Nuclear Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California 90095 6948, USA
    J Nucl Med 48:78S-88S. 2007
    ..From these data, we believe, has emerged reliable evidence in support of the notion that PET/CT offers diagnostic advantages over its individual components for the major cancers...
  8. pmc Molecular mechanisms of bone 18F-NaF deposition
    Johannes Czernin
    Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095 1782, USA
    J Nucl Med 51:1826-9. 2010
    ....
  9. doi request reprint Breast cancer
    Johannes Czernin
    Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA
    Methods Mol Biol 727:141-70. 2011
    ..Novel molecular imaging probes and devices that have been developed and translated into early clinical research protocols are also introduced...
  10. ncbi request reprint Positron emission tomography scanning: current and future applications
    Johannes Czernin
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic, UCLA School of Medicine, 10833 LeConte Avenue, Los Angeles, California 90095 6942, USA
    Annu Rev Med 53:89-112. 2002
    ..When possible, we compare the performance of PET to that of anatomical imaging. We discuss future clinical applications of this imaging modality...
  11. ncbi request reprint Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective
    J Meta
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic, and Nuclear Medicine, University of California, Los Angeles, School of Medicine, Los Angeles, CA, USA
    J Nucl Med 42:586-90. 2001
    ....
  12. pmc Comparison of CT, PET, and PET/CT for staging of patients with indolent non-Hodgkin's lymphoma
    Barbara J Fueger
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Mol Imaging Biol 11:269-74. 2009
    ..The aim was to investigate the potential impact of positron emission tomography (PET)/computed tomography (CT) as compared to PET and CT on the staging of patients with indolent lymphoma...
  13. ncbi request reprint Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer
    Jong Ho Kim
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, California 90095 6942, USA
    J Nucl Med 46:587-95. 2005
    ..The aim of this study was to compare PET with (18)F-FDG PET, in-line PET/CT, and software fusion of independently acquired CT and PET scans for staging of recurrent colorectal cancer (CRC)...
  14. ncbi request reprint Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma
    H Schoder
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic Nuclear Medicine, University of California, Los Angeles, School of Medicine, 90095 6942, USA
    J Nucl Med 42:1139-43. 2001
    ..PET imaging with (18)F-FDG is useful for staging of lymphoma as well as for monitoring of therapy. However, to our knowledge, the clinical impact of PET on staging and management of lymphoma patients has not been reported...
  15. ncbi request reprint Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective
    C S Yap
    Ahmanson Biological Imaging Center/Nuclear Medicine Clinic, Department of Molecular and Medical Pharmacology, UCLA School of Medicine, University of California, Los Angeles, USA
    J Nucl Med 42:1334-7. 2001
    ..CONCLUSION: The results of this prospective survey show that FDG PET has a major impact on the management of breast cancer patients, influencing both clinical stage and management in more than 30% of patients...
  16. ncbi request reprint Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors
    Helen Su
    Department of Molecular Medicine and Pharmacology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California at Los Angeles, 650 Charles Young Drive, Los Angeles, CA 90095, USA
    Clin Cancer Res 12:5659-67. 2006
    ....
  17. ncbi request reprint Evaluation of suspected local recurrence in head and neck cancer: a comparison between PET and PET/CT for biopsy proven lesions
    Benjamin S Halpern
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center Nuclear Medicine, UCLA School of Medicine, Los Angeles, CA 90095 6948, USA
    Eur J Radiol 62:199-204. 2007
    ..18)F-FDG PET has a high accuracy for re-staging of head and neck cancer. The purpose of this study was to determine whether the diagnostic accuracy can be further improved with integrated PET/CT...
  18. ncbi request reprint Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography
    Cecelia S Yap
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center Nuclear Medicine, UCLA School of Medicine, AR 144 CHS, Los Angeles, CA 90095 6948, USA
    Chest 129:393-401. 2006
    ....
  19. ncbi request reprint Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy
    Betty S Pio
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA USA
    Mol Imaging Biol 8:36-42. 2006
    ..We examined side-by-side FDG and FLT imaging for monitoring and predicting tumor response to chemotherapy...
  20. ncbi request reprint Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel
    Anne Gangloff
    Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
    J Nucl Med 46:1866-71. 2005
    ..We compared the PET data to data derived from direct harvesting and analysis of blood, organs, and breast carcinoma xenografts...
  21. doi request reprint 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience
    Carlos J Ledezma
    Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Eur J Radiol 71:242-8. 2009
    ..The purpose of this study was to determine whether (18)F-FDOPA PET/MRI fusion can provide precise anatomic localization of abnormal tracer uptake and how this activity corresponds to MR signal abnormality...
  22. doi request reprint Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma
    Liu Hua Wei
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Clin Cancer Res 14:3416-26. 2008
    ..The mechanisms underlying changes in metabolic activity were analyzed by measuring expression and functional activity of enzymes and transporters involved in the uptake of the studied imaging probes...
  23. ncbi request reprint Cardiac pacemakers and central venous lines can induce focal artifacts on CT-corrected PET images
    Benjamin S Halpern
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic Nuclear Medicine, UCLA School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    J Nucl Med 45:290-3. 2004
    ..PET/CT imaging can be associated with focal artifactual (18)F-FDG uptake introduced by metallic implants or contrast agents. It is unknown whether cardiac pacemakers or permanent central venous catheters can also result in such artifacts...
  24. ncbi request reprint Impact of animal handling on the results of 18F-FDG PET studies in mice
    Barbara J Fueger
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    J Nucl Med 47:999-1006. 2006
    ..The aim of this study was to determine how these factors affect assessment of tumor glucose use by (18)F-FDG PET and to develop an imaging protocol that optimizes visualization of tumor xenografts...
  25. ncbi request reprint Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome
    D H Silverman
    Ahmanson Biological Imaging Center, CHS AR 144, Department of Molecular and Medical Pharmacology, University of California, Los Angeles School of Medicine, Los Angeles, CA 90095 6942, USA
    JAMA 286:2120-7. 2001
    ..Deficits in cerebral glucose utilization have been identified in patients with cognitive dysfunction attributed to various disease processes, but their prognostic and diagnostic value remains to be defined...
  26. ncbi request reprint Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study
    Benjamin S Halpern
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, California 90095 6942, USA
    J Nucl Med 46:603-7. 2005
    ..High photon attenuation and scatter in obese patients affect image quality. The purpose of the current study was to optimize lutetium orthosilicate (LSO) PET image acquisition protocols in patients weighing > or =91 kg (200 lb)...
  27. doi request reprint Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice
    Martin A Walter
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California, USA
    J Nucl Med 51:1285-92. 2010
    ....
  28. ncbi request reprint Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability
    Benjamin S Halpern
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, California 90095 6942, USA
    J Nucl Med 45:797-801. 2004
    ..This study was performed to prospectively evaluate fast PET/CT imaging protocols using lutetium oxyorthosilicate (LSO) detector technology and 3-dimensional (3D) image-acquisition protocols...
  29. doi request reprint Engineered antibody fragments with infinite affinity as reporter genes for PET imaging
    Liu H Wei
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California, USA
    J Nucl Med 49:1828-35. 2008
    ..The objective of the present study was to evaluate a new approach for reporter gene imaging based on cell surface expression of antibody fragments that can irreversibly bind to radiometal chelates...
  30. ncbi request reprint Accuracy of PET/CT in characterization of solitary pulmonary lesions
    Shanna K Kim
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California 90095 6942, USA
    J Nucl Med 48:214-20. 2007
    ..The performance of dual-modality imaging with PET/CT for characterizing SPNs was investigated in a clinical referral setting...
  31. ncbi request reprint Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET
    Christian Waldherr
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, David Geffen School of Medicine, University of California at Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095, USA
    J Nucl Med 46:114-20. 2005
    ..The aim of this study was to evaluate, whether PET with (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) may be used to monitor noninvasively the antiproliferative effects of tyrosine kinase inhibitors...
  32. doi request reprint Utilization of positron emission tomography in the management of patients with sarcoma
    Matthias R Benz
    Departments of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California 90095, USA
    Curr Opin Oncol 21:345-51. 2009
    ..In this review, the recent literature covering all aspects of PET imaging in the management of patients with soft tissue and bone sarcomas will be discussed...
  33. ncbi request reprint Biodistribution and predictive value of 18F-fluorocyclophosphamide in mice bearing human breast cancer xenografts
    Amanda L Kesner
    Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California 90095 6942, USA
    J Nucl Med 48:2021-7. 2007
    ....
  34. ncbi request reprint Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study
    Wei Chen
    Ahmanson Biological Imaging Division and the Department of Molecular and Medical Pharmacology, Biostatistics, Radiology, University of California, Los Angeles, Los Angeles, CA 90005 6942, USA
    J Clin Oncol 25:4714-21. 2007
    ....
  35. doi request reprint Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors
    Helen Su
    Department of Molecular Medicine and Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Eur J Nucl Med Mol Imaging 35:1089-99. 2008
    ..In this study, we asked whether PET with [(18)F]gefitinib may be used to study noninvasively the pharmacokinetics of gefitinib in vivo and to image the EGFR status of cancer cells...
  36. doi request reprint Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab
    Antoni Ribas
    Division of Hematology Oncology, Department of Medicine, UCLA, Los Angeles, California, USA
    J Nucl Med 51:340-6. 2010
    ..However, there is a paucity of data demonstrating that lymphocyte proliferation does occur in humans treated with CTLA4-blocking antibodies...
  37. doi request reprint Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma
    Christiaan Schiepers
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California 90095 6942, USA
    J Nucl Med 51:720-7. 2010
    ..3'-Deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) is used as a biomarker of cell proliferation. We investigated the kinetics of (18)F-FLT during treatment of malignant glioma with bevacizumab and irinotecan...
  38. doi request reprint The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients
    Martin Allen-Auerbach
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center Nuclear Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095 6948, USA
    Radiol Clin North Am 46:199-211, vii. 2008
    ..PET/CT has evolved to become the modality of choice for staging of nodal and extranodal lymphoma, for assessing therapeutic response, and for establishing patient prognosis...
  39. doi request reprint Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas
    Barbara J Fueger
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    J Nucl Med 51:1532-8. 2010
    ..The aims of the current study were to determine whether the degree of (18)F-FDOPA uptake in brain tumors predicted tumor grade and was associated with tumor proliferative activity in newly diagnosed and recurrent gliomas...
  40. doi request reprint Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors
    Matthias R Benz
    Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, University of California at Los Angeles, Los Angeles, California, USA
    J Nucl Med 49:1038-46. 2008
    ..Knowledge of the interobserver variability of quantitative parameters is important in sarcomas as these tumors are frequently large and demonstrate heterogeneous (18)F-FDG uptake...
  41. ncbi request reprint Semiautomated analysis of small-animal PET data
    Adam L Kesner
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California 90095 6942, USA
    J Nucl Med 47:1181-6. 2006
    ..The objective of the work reported here was to develop and test automated methods to calculate biodistribution of PET tracers using small-animal PET images...
  42. ncbi request reprint Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients
    Barbara J Fueger
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, CA 90095 6942, USA
    Mol Imaging Biol 7:369-76. 2005
    ..This study was conducted to compare the clinical stage derived from 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) positron emission tomography (PET) to that of integrated PET/computed tomography (CT) in restaged breast cancer patients...
  43. ncbi request reprint Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET
    Daniel H S Silverman
    Department of Molecular and Medical Pharmacology, University of California, Los Angeles, School of Medicine, Los Angeles, CA, USA
    Mol Genet Metab 80:350-5. 2003
    ..4). These data indicate that evaluation of brain metabolism by PET in appropriately selected patients may improve the accuracy of clinical prognostic assessment...
  44. ncbi request reprint Noninvasive quantification of bowel inflammation through positron emission tomography imaging of 2-deoxy-2-[18F]fluoro-D-glucose-labeled white blood cells
    Betty S Pio
    Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, and the Greater Los Angeles Veterans Affairs Hospital System, Los Angeles, CA 90095 6942, USA
    Mol Imaging Biol 5:271-7. 2003
    ..FDG-labeled WBC's, in conjunction with PET, can be used to provide quantitative assessment of bowel inflammation noninvasively, accurately, and rapidly...
  45. ncbi request reprint Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma
    Martin Allen-Auerbach
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 6942 USA
    Mol Imaging Biol 6:411-6. 2004
    ..We sought to determine whether integrated (hardware) fused PET/CT imaging results in further improvements in staging accuracy...
  46. ncbi request reprint Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG
    Wei Chen
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
    J Nucl Med 46:945-52. 2005
    ..We characterized (18)F-FLT PET of brain gliomas and compared (18)F-FLT with (18)F-FDG PET in side-by-side studies of the same patients...
  47. ncbi request reprint PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma
    Christiaan Schiepers
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, CA 90095 6948, Los Angeles, USA
    Eur J Nucl Med Mol Imaging 30:S82-8. 2003
    ..Highly variable results have been reported on whether up- or downstaging of lymphoma with PET leads to changes in the therapeutic approach for primary lymphoma...
  48. ncbi request reprint FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma?
    Cecelia S Yap
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center Nuclear Medicine, UCLA School of Medicine, AR 259 CHS, Los Angeles, CA 90095 6948, USA
    Eur J Nucl Med Mol Imaging 29:1166-73. 2002
    ..PET is less accurate in patients with rare BAC tumors that have no invasive component...
  49. ncbi request reprint Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion
    Benjamin S Halpern
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, AR 128 CHS, 10833 Le Conte Ave, Los Angeles, CA 90095 6942, USA
    Chest 128:2289-97. 2005
    ..To compare the diagnostic accuracy of positron emission tomography (PET) and integrated PET/CT and to evaluate the performance of software fusion for staging of non-small cell lung cancer (NSCLC)...
  50. ncbi request reprint The impact of PET on the management of lung cancer: the referring physician's perspective
    Marc A Seltzer
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic Nuclear Medicine, UCLA School of Medicine, Los Angeles, California 90095 6948, USA
    J Nucl Med 43:752-6. 2002
    ..The objective of this study was to determine referring physicians' perspectives on the impact of (18)F-FDG PET on staging and management of lung cancer...
  51. ncbi request reprint Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits
    Daniel H S Silverman
    Department of Molecular and Medical Pharmacology and Ahmanson Biological Imaging Center, UCLA School of Medicine, University of California, Los Angeles 90095 6942, USA
    J Nucl Med 43:253-66. 2002
    ..The precise diagnostic role of PET and its economic impact in this context, however, have not been systematically examined previously...
  52. ncbi request reprint Standard PET/CT of the chest during shallow breathing is inadequate for comprehensive staging of lung cancer
    Martin Allen-Auerbach
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, California, USA
    J Nucl Med 47:298-301. 2006
    ..Micronodules are usually too small to be characterized reliably with 18F-FDG PET. We aimed to determine the incidence of missed pulmonary micronodules on PET/CT studies acquired during shallow breathing...
  53. ncbi request reprint Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
    George V Thomas
    Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Nat Med 12:122-7. 2006
    ..Our findings provide preclinical rationale for prospective, biomarker-driven clinical studies of mTOR inhibitors in kidney cancer and suggest that FDG-PET scans may have use as a pharmacodynamic marker in this setting...
  54. ncbi request reprint Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients
    Duska Vranjesevic
    Department of Nuclear Medicine, UCLA School of Medicine, Los Angeles, California 90095 6942, USA
    J Nucl Med 43:325-9. 2002
    ..This study was conducted to determine the ability of (18)F-FDG PET and conventional imaging (CI) to predict the outcomes in breast cancer patients who have previously undergone primary treatment...
  55. ncbi request reprint (18)F-FDG-PET/CT in evaluating response to therapy in solid tumors: where we are and where we can go
    K Herrmann
    Departments of Molecular and Medical Pharmacology, Ahmanson Translational Imaging Division, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095 1782, USA
    Q J Nucl Med Mol Imaging 55:620-32. 2011
    ..We will then review the strengths and limitations of CT (RECIST) and PET based response criteria. Finally, we will examine the role of FDG-PET/(CT) imaging for response assessments in solid tumors...
  56. ncbi request reprint The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer
    A Safaei
    Ahmanson Biological Imaging Clinic Nuclear Medicine, Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, CA 90095 6948, USA
    Clin Nephrol 57:56-62. 2002
    ..The aim of the current study was to examine the diagnostic accuracy and clinical usefulness of whole-body PET imaging for re-staging of renal cell cancer...
  57. ncbi request reprint Relationship between 18F-FDG uptake and breast density in women with normal breast tissue
    Duska Vranjesevic
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic Nuclear Medicine, UCLA School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095 6942, USA
    J Nucl Med 44:1238-42. 2003
    ..Breast density affects the mammographic detectability of breast cancer. The study aimed to evaluate the impact of breast density on the (18)F-FDG uptake of normal breast tissue...
  58. doi request reprint Radiation dose estimates for [18F]5-fluorouracil derived from PET-based and tissue-based methods in rats
    Adam L Kesner
    Molecular and Medical Pharmacology, Ahmanson Biological Imaging Division, UCLA Medical Center, Los Angeles, CA 90095 6942, USA
    Mol Imaging Biol 10:341-8. 2008
    ..In the current manuscript, normal-tissue absorbed dose estimates for the 18F-labeled chemotherapy agent [18F]5-fluorouracil ([18F]5-FU) were derived by PET imaging- and by tissue harvesting-based methods in rats...
  59. pmc Titration of variant HSV1-tk gene expression to determine the sensitivity of 18F-FHBG PET imaging in a prostate tumor
    Mai Johnson
    Department of Molecular, Cellular and Integrative Physiology, UCLA, Los Angeles, CA, USA
    J Nucl Med 50:757-64. 2009
    ..Addressing this question could determine the sensitivity of vector-mediated sr39tk PET in cancer-targeting strategies...
  60. pmc Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma
    Shahriar S Yaghoubi
    Multimodality Molecular Imaging Lab, Department of Radiology and Bioengineering, Stanford University, Stanford, CA, USA
    Nat Clin Pract Oncol 6:53-8. 2009
    ....
  61. doi request reprint Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas
    Matthias R Benz
    Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California, USA
    J Nucl Med 49:1579-84. 2008
    ..The aim of this study was to determine whether combined assessment of tumor volume and metabolic activity improves the accuracy of (18)F-FDG PET for predicting histopathologic tumor response in patients with soft-tissue sarcomas...
  62. ncbi request reprint Time-course of effects of external beam radiation on [18F]FDG uptake in healthy tissue and bone marrow
    Adam L Kesner
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095 6942, USA
    J Appl Clin Med Phys 9:2747. 2008
    ....
  63. ncbi request reprint Conventional imaging and 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of patients with previously treated Hodgkin's disease
    Jean Emmanuel Filmont
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic, UCLA School of Medicine, Los Angeles, CA, USA
    Mol Imaging Biol 6:47-54. 2004
    ..The aim of this study was to determine the ability of 2-deoxy-2-[(18)F]fluoro-d-glucose positron emission tomography (FDG-PET) to predict the clinical outcome of previously treated patients with Hodgkin's Disease (HD)...
  64. ncbi request reprint PET/CT in cancer patient management. Introduction
    Johannes Czernin
    David Geffen School of Medicine, UCLA, Los Angeles, California, USA
    J Nucl Med 48:2S-3S. 2007
  65. ncbi request reprint 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy
    Wei Chen
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    J Nucl Med 47:904-11. 2006
    ..We evaluated the amino acid and glucose metabolism of brain tumors by using PET with 3,4-dihydroxy-6-(18)F-fluoro-l-phenylalanine ((18)F-FDOPA) and (18)F-FDG...
  66. ncbi request reprint Predicting seizure-free status for temporal lobe epilepsy patients undergoing surgery: prognostic value of quantifying maximal metabolic asymmetry extending over a specified proportion of the temporal lobe
    Tina W Lin
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095 6942, USA
    J Nucl Med 48:776-82. 2007
    ..We aimed to develop an approach with which to quantitatively assess prognostically pertinent aspects of metabolic asymmetry in presurgical PET scans for forecasting postsurgical seizure-free clinical outcomes...
  67. ncbi request reprint Myocardial perfusion reserve in adults with cyanotic congenital heart disease
    Richard C Brunken
    Dept of Molecular and Medical Pharmacology, David Geffen School of Medicine at the University of California, Los Angeles, USA
    Am J Physiol Heart Circ Physiol 289:H1798-806. 2005
    ..61 mmHg x ml(-1) x g x min (SD 27), P = not significant]. These findings suggest that adult CCHD patients have remodeling of the coronary circulation to compensate for the rheologic changes attending chronic hypoxemia...
  68. ncbi request reprint Oncologic PET/CT interpretation and reporting approaches. Survey in clinical practice
    D Karantanis
    David Geffen School of Medicine at UCLA, Department of Molecular and Medical Pharmacology, 200 Medical Plaza, Suite B114, Los Angeles, California 90024, United States, E mail
    Nuklearmedizin 53:19-25. 2014
    ..To elucidate techniques most commonly used for interpreting oncologic PET/CT studies. This survey forms a basis to work on standardization of reporting and highlight the most important issues to be addressed...
  69. pmc Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign
    Matthias R Benz
    Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California 90095 1782, USA
    Cancer 116:451-8. 2010
    ..The aim of this study was to evaluate whether F18-fluorodeoxyglucose positron emission tomography (FDG PET) can differentiate malignant (MPNST) from benign PNSTs...
  70. doi request reprint FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas
    Matthias R Benz
    Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095 1782, USA
    Clin Cancer Res 15:2856-63. 2009
    ....
  71. ncbi request reprint Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation
    Jean Emmanuel Filmont
    Ahmanson Biological Imaging Clinic, Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, CA 90095, USA
    Chest 124:608-13. 2003
    ....
  72. ncbi request reprint 18F-FDG PET for staging breast cancer in patients with inner-quadrant versus outer-quadrant tumors: comparison with long-term clinical outcome
    Amy Tran
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    J Nucl Med 46:1455-9. 2005
    ..This study examined whether (18)F-FDG PET findings were differentially associated with the location of primary tumors, and with long-term prognosis, in IQ and OQ patients...
  73. pmc Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs
    Wolfgang A Weber
    Nuclear Medicine, University of Freiberg, Germany
    Nat Clin Pract Oncol 5:44-54. 2008
    ..Examples include imaging of the expression and inhibition of drug targets, noninvasive tissue pharmacokinetics, and early assessment of the tumor response...
  74. doi request reprint Technology Insight: advances in molecular imaging and an appraisal of PET/CT scanning
    Wolfgang A Weber
    Abteilung Nuklearmedizin, University of Freiburg, Hugstetterstrasse 56, 79106 Freiburg, Germany
    Nat Clin Pract Oncol 5:160-70. 2008
    ..In this Review we discuss the technical features of PET/CT, its economic aspects within the health-care system, and its role in diagnosis, staging, restaging and treatment monitoring as well as radiation planning in patients with cancer...
  75. doi request reprint Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas
    Vladimir Evilevitch
    Abteilung Nuklearmedizin University of Freiburg, Freiburg, Germany
    Clin Cancer Res 14:715-20. 2008
    ..The aim of this study was to prospectively evaluate whether positron emission tomography with (18)F-fluorodeoxyglucose (FDG-PET) allows for a more accurate evaluation of histopathologic response...
  76. ncbi request reprint Prognostic significance of fluorodeoxyglucose uptake in non-small cell lung cancer. A blurry picture?
    Wolfgang A Weber
    Clin Cancer Res 13:3105-6. 2007
  77. ncbi request reprint Conventional imaging and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of previously treated non-Hodgkin's lymphoma patients
    Jean Emmanuel Filmont
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic UCLA School of Medicine, Los Angeles, CA 90095, USA
    Mol Imaging Biol 5:232-9. 2003
    ....
  78. ncbi request reprint Translational molecular imaging
    Johannes Czernin
    Mol Imaging Biol 6:181-2. 2004
  79. ncbi request reprint The role of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography/computed tomography in monitoring the immunosuppressive therapy response of inflammatory myofibroblastic tumor
    Sebastian L Obrzut
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA
    Mol Imaging Biol 6:126-30. 2004
    ....
  80. ncbi request reprint Predicting chemotherapy response to paclitaxel with 18F-Fluoropaclitaxel and PET
    Wei Ann Hsueh
    Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095 6942, USA
    J Nucl Med 47:1995-9. 2006
    ....